

TOM DAVIS, VIRGINIA,  
CHAIRMAN

CHRISTOPHER SHAYS, CONNECTICUT  
DAN BURTON, INDIANA  
ILEANA ROS-LEHTINEN, FLORIDA  
JOHN M. McHUGH, NEW YORK  
JOHN L. MICA, FLORIDA  
GIL GUTKNECHT, MINNESOTA  
MARK E. SOUDER, INDIANA  
STEVEN C. LATOURETTE, OHIO  
TODD RUSSELL PLATTS, PENNSYLVANIA  
CHRIS CANNON, UTAH  
JOHN J. DUNCAN, JR., TENNESSEE  
CANDICE MILLER, MICHIGAN  
MICHAEL R. TURNER, OHIO  
DARRELL ISSA, CALIFORNIA  
JON C. PORTER, NEVADA  
KENNY MARCHANT, TEXAS  
LYNN A. WESTMORELAND, GEORGIA  
PATRICK T. McHENRY, NORTH CAROLINA  
CHARLES W. DENT, PENNSYLVANIA  
VIRGINIA FOXX, NORTH CAROLINA  
JEAN SCHMIDT, OHIO  
BRIAN P. BILBRAY, CALIFORNIA

ONE HUNDRED NINTH CONGRESS

# Congress of the United States

## House of Representatives

COMMITTEE ON GOVERNMENT REFORM

2157 RAYBURN HOUSE OFFICE BUILDING

WASHINGTON, DC 20515-6143

MAJORITY (202) 225-5074  
FACSIMILE (202) 225-3974  
MINORITY (202) 225-5051  
TTY (202) 225-6852

<http://reform.house.gov>

September 22, 2006

HENRY A. WAXMAN, CALIFORNIA,  
RANKING MINORITY MEMBER

TOM LANTOS, CALIFORNIA  
MAJOR R. OWENS, NEW YORK  
EDOLPHUS TOWNS, NEW YORK  
PAUL E. KANJORSKI, PENNSYLVANIA  
CAROLYN B. MALONEY, NEW YORK  
ELIJAH E. CUMMINGS, MARYLAND  
DENNIS J. KUCINICH, OHIO  
DANNY K. DAVIS, ILLINOIS  
WM. LACY CLAY, MISSOURI  
DIANE E. WATSON, CALIFORNIA  
STEPHEN F. LYNCH, MASSACHUSETTS  
CHRIS VAN HOLLEN, MARYLAND  
LINDA T. SANCHEZ, CALIFORNIA  
C.A. DUTCH RUPPERSBERGER,  
MARYLAND  
BRIAN HIGGINS, NEW YORK  
ELEANOR HOLMES NORTON,  
DISTRICT OF COLUMBIA

BERNARD SANDERS, VERMONT,  
INDEPENDENT

Andrew C. von Eschenbach, M.D.  
Acting Commissioner  
U.S. Food and Drug Administration  
U.S. Department of Health and Human Services  
5600 Fishers Lane, Room 15-47  
Rockville, MD 20857

Dear Dr. von Eschenbach,

Thank you for your September 13, 2006 response to my letter regarding the increasing use of phenylephrine in oral nasal decongestants. As you will recall, I enclosed in my letter a peer-reviewed letter to the editor authored by Dr. Leslie Hendeles and Dr. Randy Hatton that was recently published in the Journal of Allergy and Clinical Immunology. Dr. Hendeles and Dr. Hatton concluded that there is little evidence showing that the drug is any more effective than placebo at the maximum FDA-approved dose (10 mg).

I was disappointed with your response that you will not convene an advisory meeting to investigate what appears to be serious lack of evidence that phenylephrine actually works to relieve nasal congestion. I am writing again to share some new information that I hope will change your decision.

Since my August 23, 2006 letter to you, it has been brought to my attention that another study comparing the effectiveness of phenylephrine to both placebo and to pseudoephedrine was recently conducted, and is now completed. According to the attached listing on ClinicalTrials.gov, in January 2006, Schering-Plough began a "Phase 3, single-dose, investigator-blind, randomized, placebo-controlled, crossover study" comparing the effect of phenylephrine with those of placebo and pseudoephedrine on nasal congestion in those with seasonal allergic rhinitis.

It is my understanding that Dr. Hendeles recently contacted the principal investigator of the Schering-Plough trial to request information about its outcome. Although he was unable to share the unpublished results of the trial, the principal investigator apparently indicated his agreement with Dr. Hendeles' conclusions regarding phenylephrine set forth in Dr. Hendeles' letter to the editor.

Andrew C. von Eschenbach, M.D.  
September 22, 2006  
Page 2

It is my further understanding that Dr. Hendeles then contacted Schering-Plough to request access to the results of the trial. The company apparently refused, stating that the results are not yet available and that they would "share the findings with regulatory authorities and publish them in a peer reviewed journal as appropriate."

Given what appears to be mounting evidence that phenylephrine is not effective at the FDA-monograph dose, I urge you to compel Schering-Plough to disclose the results of their trial, and that you make those results publicly available. If indeed there is proof that phenylephrine is not effective in relieving symptoms of nasal congestion, consumers have a right to know. FDA has a duty to arm Americans with the information they need so that they don't waste their hard-earned money on medicines that do not work.

Please provide a response to this letter by October 10, 2006.

Sincerely,

A handwritten signature in black ink, appearing to read "Henry A. Waxman", followed by a long horizontal flourish.

Henry A. Waxman  
Ranking Minority Member

Attachment

## **The Effects of Phenylephrine Compared With Those of Placebo and Pseudoephedrine on Nasal Congestion in Subjects With Seasonal Allergic Rhinitis (SAR) (Study P04579)(COMPLETED)**

**This study has been completed.**

**Sponsored by: Schering-Plough**

**Information provided by: Schering-Plough**

**ClinicalTrials.gov Identifier: NCT00276016**

### **Purpose**

This is a Phase 3, single-dose, investigator-blind, randomized, placebo-controlled, crossover study, conducted at a single site in Austria, outside of the normal grass pollen season. An allergic reaction will be induced by exposing subjects to grass pollen in the Vienna Challenge Chamber (VCC). Subjects will receive a single dose of each of the following treatments according to a randomization sequence: Phenylephrine 12 mg immediate-release capsule, pseudoephedrine 60 mg immediate-release tablet, and placebo capsule. There will be a minimum of a 5-day washout period between each treatment. Subjects will complete symptom evaluations throughout the study. The nasal decongestant effects of phenylephrine will be compared to those of placebo using the subjective symptom evaluations. The safety profile (adverse events and vital signs) of the treatments will also be evaluated.

Condition	Intervention	Phase
Rhinitis, Allergic, Seasonal	Drug: phenylephrine, pseudoephedrine	<u>Phase III</u>

MedlinePlus related topics: [Allergy](#)

Study Type: Interventional

Study Design: Treatment, Randomized, Single Blind, Placebo Control, Crossover Assignment, Safety/Efficacy Study

Official Title: Crossover Study of the Decongestant Effect of Phenylephrine Compared With Placebo and Pseudoephedrine as Active Control in SAR Subjects Exposed to Pollen in the Vienna Challenge Chamber

Further study details as provided by Schering-Plough:

Expected Total Enrollment: 39

Study start: January 2006

## Eligibility

Ages Eligible for Study: 18 Years - 55 Years, Genders Eligible for Study: Both  
Criteria

### Inclusion Criteria:

- Ages between 18 and 55 years, of either sex, and of any race.
- A history of SAR for at least 2 years, as diagnosed by the investigator, another physician, or subject-provided history.
- The following minimum scores at some point during each of the 120-minute screening period challenge sessions:
  - Score of at least 2 (moderate) for nasal congestion.
  - Score of at least 6 for combined nasal symptoms (symptoms are rhinorrhea, nasal congestion, sneezing, nasal itching).
  - Score of at least 2 for combined non-nasal symptoms (symptoms are eye itching/burning, eye tearing, itching of ears/palate).
- Positive skin prick test to relevant grass allergen to be used in the chamber, unless previously done within 12 months. IgE-mediated hypersensitivity to the appropriate allergen must be documented by a positive response to the skin prick test with wheal diameter  $\geq 3$  mm larger than diluent control.
- A negative urine pregnancy test prior to treatment with study medication for all female subjects of childbearing potential and a negative urine pregnancy test obtained at monthly intervals during study participation.
- Use of a medically accepted method of birth control, ie, double-barrier method (eg, condom and spermicide), oral contraceptive, Depo-Provera or Norplant, for female subjects of childbearing potential prior to screening and during the study. Women of childbearing potential should be counseled in the appropriate use of birth control while in the study. Vasectomy or tubal ligation is considered a single barrier. Women who are not currently sexually active must agree and consent to use one of the above-mentioned methods if they become sexually active while participating in the study.
- Good health and freedom from any clinically significant disease (other than SAR) that would interfere with the study schedule or procedures, or compromise the subject's safety.
- Willingness to give written informed consent and adhere to dose and visit schedules.
- The appropriate washout times from the prohibited medications.
- Clinical laboratory tests (CBC, blood chemistries, urinalysis, and ECG results) at screening within normal limits or clinically acceptable to the investigator

### Exclusion Criteria :

- Pregnancy, intention of becoming pregnant, or lactation.
- A situation or any condition that, in the opinion of the investigator, may interfere with optimal participation in the study.
- Use of any investigational drugs, including placebo, within 30 days of Screening.
- Current participation in any other clinical study.
- Staff personnel directly involved with this study.
- Dependence (in the opinion of the investigator) upon nasal, oral, or ocular decongestants, nasal topical antihistamines, or nasal steroids.
- Nasal structural abnormalities, including large nasal polyps or marked septal deviation, that significantly interfere with nasal airflow.
- Previous enrollment (ie, signed informed consent) into this study.
- History of rhinitis medicamentosa.
- A history of anaphylaxis or severe or serious reaction to skin testing.
- A known potential for hypersensitivity, allergy, or idiosyncratic reaction to the study drugs or excipients.
- Narrow-angle glaucoma, increased intraocular pressure, urinary retention, hypertension, severe coronary artery disease, ischemic heart disease, diabetes mellitus, hyperthyroidism, renal impairment, or prostatic hypertrophy, and current treatment with monoamine oxidase (MAO) inhibitors.
- An upper or lower respiratory tract infection within 4 weeks before screening, or a respiratory infection any time during the treatment phase of the study.

## **Location Information**

Study chairs or principal investigators

Friedrich Horak, MD, Principal Investigator, Allergy Center Vienna West

## **More Information**

Study ID Numbers: P04579

Last Updated: April 28, 2006

Record first received: January 11, 2006

ClinicalTrials.gov Identifier: [NCT00276016](#)

Health Authority: Austria: Federal Ministry for Health and Women

ClinicalTrials.gov processed this record on 2006-09-22

[U.S. National Library of Medicine, Contact NLM Customer Service](#)

[National Institutes of Health, Department of Health & Human Services](#)

[Copyright, Privacy, Accessibility, Freedom of Information Act](#)